openPR Logo
Press release

Converging Factors Driving the Growth of Transdermal Patches for Neurology Indications

10-17-2017 05:06 PM CET | Health & Medicine

Press release from: Greystone Research Associates

(Amherst, NH) – Despite recent progress in a number of therapeutic sectors, progress toward curative medicine for neurological and related central nervous system disorders has remained elusive. The result is a therapeutic sector that relies heavily on control of symptoms and palliative care. This disappointing picture is being exacerbated by disease trends that are increasing the morbidity and mortality associated with CNS ailments in the general population. These trends include the growing incidence of neurological disorders associated with longevity and aging, and significant increases in the number of children diagnosed with autism.

Neurological disorders are highly prevalent worldwide. The World Health Organization’s Global Burden of Disease report drew the attention of the international health community to the fact that the burden of mental and neurological disorders has been seriously underestimated by traditional epidemiological methods that took into account only mortality, but not disability rates. This report specifically showed that while the mental and neurological disorders are responsible for about one per cent of deaths, they account for almost 11 per cent of disease burden the world over.

Advancing age is the most significant risk factor for neurological disease. As the U.S. population grows older, the burden of neurological disease becomes ever more apparent. Costs associated with neurological diseases are expected to increase dramatically within the next few years and decades. Currently, hospital costs paid by Medicare and Medicaid are almost three times higher for those with neurological disease than for other conditions. Unless new and better means are discovered and deployed to manage these impairments, their costs are expected to increase dramatically over the next five years.

Because diseases of the central nervous system often result in compromised cognitive and/or motor skills that can increase the level of involuntary non-compliance with therapeutic protocols, transdermal delivery of drugs targeting CNS disorders is generally viewed as an approach that can increase patient safety and improve outcomes. In addition to the handful of FDA-approved transdermal CNS products, more than a dozen companies are currently pursuing a range of APIs in transdermal delivery systems that target neurological and CNS conditions. While none of these development-stage candidates is curative, the benefits they can offer in terms of patient ease-of-use, product safety and overall quality-of-care are expected to result in reduced morbidity and more effective symptom management for afflicted patients.

Greystone’s analysis of the global transdermal CNS market includes detailed product analysis, an assessment of factors influencing demand for transdermal CNS drug products, the key players in this segment, the regulatory and industry environment, and the dynamics of patient care that will affect market development. Available data also includes forecasts for the growth of transdermal CNS products.

More information is available at www.greystoneassociates.org .

Contact:

Mark Smith
Voice: 603-595-4340
Fax: 603-218-7020
www.greystoneassociates.org

Source: Greystone Research Associates

About Greystone

Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Contact:

Mark Smith
Greystone Research Associates
98 Route 101A
Amherst, NH 03031 USA
Voice: 603-595-4340
Fax: 603-218-7020
www.greystoneassociates.org

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Converging Factors Driving the Growth of Transdermal Patches for Neurology Indications here

News-ID: 775531 • Views: 675

More Releases from Greystone Research Associates

Seeking to Capitalize on New Device Technology Drug Companies are Reformulating …
(Amherst, NH) – As the pace of competition increases within the pharmaceutical and biotech industries, the concept of life cycle management is becoming a key component of drug product management. Much of the recent emphasis in this area has centered on efforts to extend patent rights protection. While reformulation has been and is an important approach, efforts to prolong IP benefits have only recently involved IV-to-SC drug re-engineering. This migration
Antibacterial Treatments that don’t Rely on Antibiotics Winding their way thro …
(Amherst, NH) – As bacteria grow resistant to conventional antibiotics, alternatives are being investigated, including antibodies, probiotics, bacteriophages, and antimicrobial peptides. The quest to replace the current generation of antibiotics is complicated by the methods that bacteria have acquired to evade attempts to destroy them – methods often referred to a virulence factors. A microorganism can possess a wide array of virulence factors. They may only express these virulence factors when
3D Printing Positioned to Address Issues that have Prevented Wide Adoption of Mi …
(Amherst, NH) – The promise of commercial microneedle drug delivery has been on the horizon for more than a decade. Like other compelling medical device innovations such as noninvasive glucose monitoring, the potential of the technology has yet to be realized due to the inability to solve the issues of reliable product performance from unit to unit and across a wide user population. To fully address the unmet need these technologies
Analysis of the Oncology Drug Pipeline Reveals Evolving Therapy Correlations and …
(Amherst, NH) – The almost two thousand active oncology clinical trials paint a picture of an evolving therapeutic sector that has established players moving quickly to realize the expanded benefits of recent treatment protocols. A dozen targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. There approaches have attracted a growing number of drug developers anxious to profit from

All 5 Releases


More Releases for CNS

Neuro Critical Care Market Insights in terms of volume and value 2018 to 2028(Mo …
Neuro critical care is an emerging field that combines the specialties that link neurology, neurosurgery, and critical care. Just as the field has evolved from primary focus on post-operative care to elective neurosurgical patients, the focus towards the resuscitation of neurological emergency cases such as traumatic brain injury or subarachnoid hemorrhage, which remain a clinical challenge. The neuro critical care market is strongly driven by the increasing focus, awareness, and
Global CNS Therapeutics Market Size, Status and Forecast 2018-2025
CNS Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the CNS Therapeutics development in United States, Europe and China. Get Sample@ https://www.researchbeam.com/global-cns-therapeutics-size-status-and-forecast-2018-2025-market/request-sample Central nervous system (CNS) disease is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. The condition may be an inherited metabolic disorder; the result of damage
CNS Lymphoma Market Key Trends and Opportunity Analysis 2020
Central Nervous System (CNS) lymphoma is also known as primary CNS lymphoma and microglioma, is a type of intracranial tumor observed in patients diagnosed with severe immunosupression (typically patients with AIDS). Primary CNS lymphoma initiates in the spinal cord, brain or meninges. While, most of primary CNS lymphomas are B-cell lymphomas and T-cell lymphomas are rare. The sign and symptoms of primary CNS lymphoma are diplopia, dysphagia, vertigo, monocular vision
CNS Cluster Addiction Drug Development Pipeline Review, 2017
ReportsWorldwide has announced the addition of a new report title CNS Cluster Addiction Drug Development Pipeline Review, 2017 to its growing collection of premium market research reports. The central nervous system (CNS) addiction cluster report provides an overview of the CNS Clusters pipeline landscape. The report provides comprehensive information on the therapeutics under development, and key players involved in therapeutic development for Alcohol Addiction, Drug Addiction, Nicotine Addiction, Opium (Opioid) Addiction
US CNS Disorders Drug Pipeline Insight 2014
The Central Nervous System (CNS) disorders market in US is one of the largest segments of pharmaceuticals industry. In US, the numbers of CNS disorders have increased at an alarming rate, while the available therapies were unable to meet the market requirements. There has been steady to rapid growth in the market for CNS disorder, especially over the past two decades. The market for CNS therapies is one of the
CNS Therapeutics Market Research Report 2016
“Global CNS Therapeutics Market Research Report 2016” Order This Report by calling BigMarketResearch.com at +1-971-202-1575 Notes: Production, means the output of CNS Therapeutics Revenue, means the sales value of CNS Therapeutics This report studies CNS Therapeutics in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering Pfizer, Inc. (USA) Johnson & Johnson (USA) Bristol-Myers Squibb